Clinica Baviera (CBAV) AI Stock Analysis

• Market Cap: €622.79M
• Dividend Yield: 3.33%
• Average Volume (3M): 5.77K
• Price to Earnings (P/E): 15.2
• Beta (1Y): 0.28
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: ES
• Employees: 1,706
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Diagnostics & Research
• EPS (TTM): N/A
• Shares Outstanding: 16,307,580
• 10 Day Avg. Volume: 8,052
• 30 Day Avg. Volume: 5,768
• PEG Ratio: 1.30
• Price to Book (P/B): 6.25
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 16.72
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Clinica Baviera's overall stock score reflects its strong financial performance, characterized by impressive revenue and profit growth, a robust balance sheet with no debt, and efficient cash flow management. The stock's valuation is reasonable with a solid dividend yield, providing investor appeal. Technical analysis shows mixed signals, with potential short-term resistance but longer-term support. Overall, the company is well-positioned financially, though investor sentiment remains neutral, as indicated by technical indicators.

Clinica Baviera Business Overview & Revenue Model

Company Description

Clinica Baviera (CBAV) is a prominent healthcare company specializing in ophthalmology services. It operates a network of clinics across Europe, particularly in Spain, Germany, and Italy, offering a wide range of eye care treatments. The company is known for its advanced medical procedures, including laser eye surgery, cataract surgery, and other corrective eye surgeries, catering to patients seeking both medical and cosmetic solutions for their vision needs.

How the Company Makes Money

Clinica Baviera generates revenue primarily through the provision of specialized ophthalmology services. Its key revenue streams include fees from consultations, diagnostic evaluations, and a variety of surgical procedures such as LASIK, lens implants, and cataract surgeries. Additionally, the company may offer financing options for patients, which can encourage more clients to undergo elective procedures. Clinica Baviera also benefits from partnerships with healthcare insurance providers, which can cover a portion of the treatment costs, thereby increasing patient accessibility and clinic utilization. The company's established reputation and wide geographic presence allow it to attract a large and diverse patient base, further contributing to its revenue.

Clinica Baviera Financial Statement Overview

Summary

Clinica Baviera exhibits strong financial health, driven by consistent revenue and profit growth, a robust balance sheet with no debt, and efficient cash flow management. The company's financial statements reflect a well-managed enterprise with strong profitability and stable operations. While cash flow growth is moderate, the overall financial position is solid, providing a strong foundation for future growth.

Income Statement

Clinica Baviera has demonstrated strong and consistent revenue growth over the past years, with a Revenue Growth Rate of 16.74% from 2023 to 2024. The Gross Profit Margin for 2024 is robust at 88.37%, reflecting efficient cost management. The company also maintains healthy profitability with a Net Profit Margin of 15.31% and an EBIT Margin of 21.20%, indicating strong operational efficiency. However, there is room for improvement in EBITDA Margin, which stands at 29.73%.

Balance Sheet

The company's balance sheet is solid, with a Debt-to-Equity Ratio of 0.00 in 2024, showcasing no reliance on debt financing. The Equity Ratio is strong at 45.72%, indicating a well-capitalized structure. Return on Equity is impressive at 41.49%, reflecting effective use of shareholders' equity to generate profit. The balance sheet stability is a significant strength for Clinica Baviera.

Cash Flow

Clinica Baviera has shown consistent Free Cash Flow generation, with a Free Cash Flow to Net Income Ratio of 0.90 in 2024, indicating efficient conversion of net income into cash. The Operating Cash Flow to Net Income Ratio is healthy at 1.56, suggesting strong cash generation from operations. However, the Free Cash Flow Growth Rate is modest at 3.19%, indicating limited growth in cash flows compared to previous years.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
262.65M	224.92M	198.45M	172.73M	122.63M
	Gross Profit
232.08M	197.85M	172.95M	151.25M	107.37M
	EBIT
55.67M	50.01M	41.49M	39.43M	20.51M
	EBITDA
78.11M	67.22M	56.15M	53.49M	34.06M
	Net Income Common Stockholders
40.20M	35.97M	29.52M	27.39M	13.94M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
38.58M	51.24M	38.99M	32.27M	26.94M
	Total Assets
211.95M	178.64M	150.10M	133.81M	120.92M
	Total Debt
0.00	47.41M	39.98M	51.56M	54.84M
	Net Debt
-10.14M	39.11M	20.81M	41.75M	44.02M
	Total Liabilities
113.59M	86.37M	81.74M	78.42M	76.02M
	Stockholders Equity
96.92M	91.00M	67.34M	54.60M	44.49M
Cash Flow		Free Cash Flow
36.25M	35.13M	39.35M	36.28M	23.64M
	Operating Cash Flow
62.76M	57.81M	53.38M	46.86M	31.46M
	Investing Cash Flow
-20.90M	-44.31M	-12.56M	-17.08M	-21.40M
	Financing Cash Flow
-39.91M	-24.37M	-31.45M	-30.80M	-3.15M

Clinica Baviera Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 38.20
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:CBAV, the sentiment is Positive. The current price of 38.2 is above the 20-day moving average (MA) of 36.54, above the 50-day MA of 35.37, and above the 200-day MA of 33.89, indicating a bullish trend. The MACD of 1.04 indicates Negative momentum. The RSI at 65.57 is Neutral, neither overbought nor oversold. The STOCH value of 42.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ES:CBAV.

Clinica Baviera Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SAN	80 Outperform	£104.55B	7.99	13.26%	2.47%	1.26%	20.56%
R4	78 Outperform	€556.50M	17.35	21.57%	3.19%	21.18%	23.01%
CBAV	76 Outperform	€622.79M	15.20		3.33%	―	―
BBVA	76 Outperform	€77.04B	7.45	19.33%	4.33%	20.72%	27.50%
MAP	73 Outperform	€10.64B	11.07		3.63%	―	―
Sector *	52 Neutral	$5.15B	3.02	-44.64%	2.83%	16.44%	-0.47%

Clinica Baviera Corporate Events

Clínica Baviera Announces Ordinary General Meeting of Shareholders

Clínica Baviera’s Board of Directors has announced the convening of its Ordinary General Meeting of Shareholders on May 27, 2025, with a second call on May 28, 2025, if necessary. The meeting will address several key agenda items, including the approval of annual accounts, management reports, and directors’ remuneration, as well as the re-election of auditors. This meeting is crucial for stakeholders as it will determine the company’s financial and strategic direction for the upcoming year.

Clinica Baviera Announces 2024 Dividend Details

Clinica Baviera has announced the details of its upcoming dividend distribution for the 2024 financial year, with a fixed unit amount of 1.57 euros gross per share. The Ordinary General Meeting has been convened to finalize the payment, which will be facilitated by CaixaBank and processed through IBERCLEAR, with relevant dates set for June 2025.

Clínica Baviera Share Sale Targets Qualified Investors

Aier Eye International (Europe), S.L.U. and Vito Gestión Patrimonial, S.L. are exploring the sale of up to 8% of Clínica Baviera’s share capital through an accelerated bookbuilt offering, targeting qualified investors. Alantra Equities is coordinating the operation, which will not provide proceeds to the company, and has agreements in place to restrict further share sales by the sellers for a specified period post-operation.

Clínica Baviera Share Sale Targeting Qualified Investors

Aier Eye International (Europe) and Vito Gestión Patrimonial are exploring the sale of up to 8% of Clínica Baviera’s share capital through an accelerated bookbuilt offering, targeting qualified investors. Alantra Equities has been appointed to manage the transaction, which will not provide proceeds to the company, and the sellers have agreed to a lock-up period post-transaction.

Clinica Baviera Proposes 2024 Dividend Distribution

The Board of Directors of Clinica Baviera has proposed to distribute a dividend of 1.57 euros gross per share from the 2024 financial year results. The distribution date and paying entity details will be announced once the Ordinary General Meeting of Shareholders is called.